Overview

• Researchers question whether these drugs can significantly reduce dementia morbidity at scale.
• The treatments show small cognitive benefits but come with substantial risks, including brain swelling and bleeding.
• High costs and stringent eligibility criteria limit accessibility for most patients.
• Regulatory bodies in the UK and Europe remain cautious about approval.
• Experts emphasize the need for balanced information to help patients make informed decisions.